Quote this publication Share Print

AVASTIN

-
Opinions on drugs - Posted on May 25 2011

Reason for request

Re-assessment of AB and IAB in the indication "First-line treatment of patients with metastatic breast cancer in combination with paclitaxel", in compliance with article R 163-21 of the French Social Security Code.

-


Clinical Benefit

Low

Because of uncertainties about the benefit of adding to AVASTIN to paclitaxel chemotherapy in metastatic breast cancer (see previous chapter), the Transparency Committee considers that the actual benefit provided by AVASTIN is low.


Clinical Added Value

no clinical added value

Given the current data, the Transparency Committee considers that AVASTIN does not provide an improvement in actual benefit (IAB level V) in the management of patients with metastatic breast cancer who are HER2 negative or who are not eligible for treatment with Herceptin.


Contact Us

Évaluation des médicaments

See also